Returning for the third year, ICI (Immune Checkpoint Inhibitors) Europe 2017 focuses exclusively on how to deliver maximum clinical benefit through immune checkpoint monotherapy and combinations. This meeting will deliver practical learning on what it takes to develop the next generation of ICI drugs, from pathway validation to clinical success.
This event is not just another broad immuno-oncology meeting. It focuses specifically on the preclinical, translational and clinical challenges that drug developers face in advancing more checkpoint inhibitors onto the market. Combining data driven case studies with interactive experience sharing sessions, this year’s program will provide cutting edge insights into novel checkpoint pathways, more predictive preclinical models, the optimal combination strategies, patient stratification biomarkers and emerging clinical trial data.
“The talks were high quality and the interaction among participants was excellent.”
“Strong program, great speakers and a genuine focus on identifying solutions”